INM Stock Analysis: Buy, Sell, or Hold?
INM - InMed Pharmaceuticals Inc. Common Shares
$1.30
0.01 (0.78%)
▲
5d:
-5.79%
30d:
-9.08%
90d:
-13.9%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When INM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INM shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INM is currently trading at $1.30, which is considered oversold relative to its 30-day fair value range of $1.33 to $1.48.
Technical Outlook: Technically, INM is in a uptrend. The price is currently testing key support at $1.28. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INM scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+1450.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INM is in a uptrend. The price is currently testing key support at $1.28. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INM scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+1450.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.33 -
$1.48
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1450.4% below Wall St target ($20.00)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.33 -
$1.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.28
Resistance Level
$1.43
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Wall Street Target
$20.00
(+1450.4%)
Revenue Growth (YoY)
-26.2%
Profit Margin
-172.2%
Share & Embed Analysis
Last updated: September 14, 2026 9:55 AM ET
Data refreshes hourly during market hours. Next update: 10:55 AM
Data refreshes hourly during market hours. Next update: 10:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
